- Conditions
- Glycogen Storage Disease Type III
- Interventions
- UX053, Placebo, Antipyretic, H2 Blocker, H1 Blocker
- Biological · Other · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Orange, California • Atlanta, Georgia • Philadelphia, Pennsylvania + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 4,633
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
- Conditions
- Human Immunodeficiency Virus
- Interventions
- Placebo, Pembrolizumab
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Immune Checkpoint Inhibitor-Related Colitis
- Interventions
- Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsules, Placebo Vedolizumab, Sulfamethoxazole-Trimethoprim, Placebo for Sulfamethoxazole-Trimethoprim
- Drug · Other
- Lead sponsor
- Shilpa Grover, MD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Dental Caries
- Interventions
- C16G2 Varnish, Placebo Varnish
- Drug
- Lead sponsor
- Armata Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Kalispell, Montana • Bedford, Texas • Irving, Texas
- Conditions
- Asthma
- Interventions
- PLACEBO, MEDI528 9 mg/kg
- Other · Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Winston-Salem, North Carolina + 1 more
- Conditions
- Healthy, Atopic Dermatitis
- Interventions
- LY3872386, Prednisone, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Anaheim, California • Daytona Beach, Florida
- Conditions
- End Stage Renal Disease, Thrombosis
- Interventions
- AB002 Dose 1, AB002 Dose 2, placebo
- Drug
- Lead sponsor
- Aronora, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Hepatitis E, Immunisation
- Interventions
- HEV 239, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Schizophrenia
- Interventions
- AQW051, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3,317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more
- Conditions
- Alopecia, Androgenetic
- Interventions
- TDM-105795, Placebo
- Drug
- Lead sponsor
- Technoderma Medicines Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- San Diego, California • College Station, Texas
- Conditions
- Wound Infection, Abscess, Systemic Inflammation, Cellulitis
- Interventions
- Single-Dose IV Oritavancin Diphosphate, IV Vancomycin, Placebo
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 968 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Healthy Study Participants
- Interventions
- UCB0599, Esomeprazole, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 502 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Rochester, New York
- Conditions
- Drug Abuse
- Interventions
- Ramelteon, triazolam, and placebo (56 possible combinations total)
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Atopic Dermatitis
- Interventions
- Tezepelumab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
- Conditions
- Healthy
- Interventions
- tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cutaneous Squamous Cell Carcinoma, Actinic Keratoses, Skin Cancer, Organ Transplant Recipients, Immunotherapy
- Interventions
- Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • St Louis, Missouri
- Conditions
- Insomnia, Primary Insomnia, Psychophysiologic Insomnia
- Interventions
- Zolpidem, Sugar Pill
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Influenza Vaccine
- Interventions
- Cam2020 M2SR H3N2 influenza vaccine, Fluzone HD IIV, IN Placebo, IM Placebo
- Biological · Other
- Lead sponsor
- FluGen Inc
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 6
- States / cities
- Port Orange, Florida • Meridian, Idaho • Lenexa, Kansas + 3 more
- Conditions
- Postoperative Pain Management, Urolithiasis
- Interventions
- Intranasal Ketoralac, Placebo
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Pain, Chronic Pain, Hyperalgesia
- Interventions
- Ketamine, Placebos
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 60
- States / cities
- Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more